The article published in the EMBO journal states that scientists have discovered a specific protein associated with drug resistance that could lead to new chemotherapy tools. Researchers have pointed out the role of f FOXO1 in chemotherapeutic resistance. In addition, through recombinant mouse proteins, they have identified a potential chemotherapy tool that is, constructing a short segment of amino acids: peptides.
There are many forms of cancer drugs. Among them, taxane chemicals are used for the treatment of advanced cancer. However, as time goes by, the taxane becomes less effective. Cancer cells communicate through other pathways. In this study, the researchers focused on how cancer cells develop other pathways and how to produce drug resistance.
Cells need energy functions. Kinases help chemicals react back and forth in specific molecules, usually in proteins. This activity will burn cell function. The scientists studied the serine / threonine kinase AKT. AKT helps cells survive, playing a very important role in many kinds of cancer. It can close the AKT drugs to improve the effectiveness of chemotherapy. However, due to the inherent complexity of cell communication, this therapy itself may allow tumor survival.
In this study, scientists used taxanes on cancer cells to block or inhibit AKT action, and they found that taxanes prevented FOXO1 protein from migrating cells to the nucleus. FOXO1 stays in the nucleus. In another protein, it becomes signal of active and improperly begins, helping cancer survive and produce drug resistance. "This is why AKT inhibitors are not approved by clinical trials. However, when FOXO1 migrates out of the nucleus, it binds to a protein called IQGAP1 scaffold. Binding action will prevent chemotherapy resistance. "We also found that the combination of taxane and FOXO1-derived inhibitors can inhibit cancer growth." By the way, Flarebio offers high-quality recombinant proteins like recombinant COLEC12 for your research.
没有评论:
发表评论